Regeneron Pharmaceuticals Rating Reiterated by TheStreet (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating reaffirmed by research analysts at TheStreet in a report released on Tuesday, Analyst Ratings Network reports.
The analysts wrote, “Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a hold with a ratings score of C+. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company’s earnings per share.”
Other equities research analysts have also recently issued reports about the stock. Analysts at BMO Capital Markets downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, January 15th. They now have a $331.00 price target on the stock. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Friday, January 10th. They now have a $340.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $323.00 to $344.00 in a research note to investors on Friday, December 20th. They now have an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $299.74.
In other Regeneron Pharmaceuticals news, VP Douglas Mccorkle sold 4,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $290.00, for a total transaction of $1,160,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.10% on Tuesday, hitting $292.28. 218,083 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $154.16 and a 52 week high of $319.83. The stock’s 50-day moving average is $278.2 and its 200-day moving average is $275.9. The company has a market cap of $28.709 billion and a P/E ratio of 41.57.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $2.40 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.92 by $1.48. The company had revenue of $597.00 million for the quarter, compared to the consensus estimate of $501.93 million. During the same quarter in the prior year, the company posted $1.89 earnings per share. The company’s quarterly revenue was up 39.6% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $3.89 EPS for the current fiscal year.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.